Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis
- PMID: 33769475
- DOI: 10.1093/eurheartj/ehab171
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis
Abstract
Aims: An interrelation between cancer and thrombosis is known, but population-based studies on the risk of both arterial thromboembolism (ATE) and venous thromboembolism (VTE) have not been performed.
Methods and results: International Classification of Disease 10th Revision (ICD-10) diagnosis codes of all publicly insured persons in Austria (0-90 years) were extracted from the Austrian Association of Social Security Providers dataset covering the years 2006-07 (n = 8 306 244). Patients with a history of cancer or active cancer were defined as having at least one ICD-10 'C' diagnosis code, and patients with ATE and/or VTE as having at least one of I21/I24 (myocardial infarction), I63/I64 (stroke), I74 (arterial embolism), and I26/I80/I82 (venous thromboembolism) diagnosis code. Among 158 675 people with cancer, 8559 (5.4%) had an ATE diagnosis code and 7244 (4.6%) a VTE diagnosis code. In contrast, among 8 147 569 people without cancer, 69 381 (0.9%) had an ATE diagnosis code and 29 307 (0.4%) a VTE diagnosis code. This corresponds to age-stratified random-effects relative risks (RR) of 6.88 [95% confidence interval (CI) 4.81-9.84] for ATE and 14.91 (95% CI 8.90-24.95) for VTE. ATE proportion was highest in patients with urinary tract malignancies (RR: 7.16 [6.74-7.61]) and lowest in patients with endocrine cancer (RR: 2.49 [2.00-3.10]). The corresponding VTE proportion was highest in cancer of the mesothelium/soft tissue (RR: 19.35 [17.44-21.47]) and lowest in oropharyngeal cancer (RR: 6.62 [5.61-7.81]).
Conclusion: The RR of both ATE and VTE are significantly higher in persons with cancer. Our population-level meta-data indicate a strong association between cancer, ATE and VTE, and support the concept of shared risk factors and pathobiology between these diseases.Relative risk of ATE and VTE in persons with a cancer diagnosis code versus persons without a cancer diagnosis code.
Keywords: Arterial occlusive diseases; Embolism; Neoplasms; Thrombosis; Venous thromboembolism.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.
Comment in
-
Double trouble for cancer patients.Eur Heart J. 2021 Jun 14;42(23):2308-2310. doi: 10.1093/eurheartj/ehab252. Eur Heart J. 2021. PMID: 33997898 No abstract available.
Similar articles
-
Incidence of arterial and venous thromboembolism in cancer patients- insights from more than 5,000,000 patients.J Thromb Thrombolysis. 2025 Mar;58(3):370-379. doi: 10.1007/s11239-025-03083-5. Epub 2025 Mar 10. J Thromb Thrombolysis. 2025. PMID: 40064841
-
Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study.Thromb Res. 2022 Jun;214:93-105. doi: 10.1016/j.thromres.2022.04.016. Epub 2022 Apr 29. Thromb Res. 2022. PMID: 35525202
-
High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.J Rheumatol. 2019 Mar;46(3):285-293. doi: 10.3899/jrheum.170896. Epub 2018 Nov 1. J Rheumatol. 2019. PMID: 30385704
-
Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis.Int J Hematol. 2020 Nov;112(5):650-657. doi: 10.1007/s12185-020-02954-2. Epub 2020 Jul 24. Int J Hematol. 2020. PMID: 32710431
-
Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis.J Thromb Haemost. 2020 Sep;18(9):2274-2286. doi: 10.1111/jth.14936. Epub 2020 Jul 21. J Thromb Haemost. 2020. PMID: 32484606
Cited by
-
Chest Pain in Cancer Patients: Prevalence of Myocardial Infarction and Performance of High-Sensitivity Cardiac Troponins.JACC CardioOncol. 2023 Aug 26;5(5):591-609. doi: 10.1016/j.jaccao.2023.08.001. eCollection 2023 Oct. JACC CardioOncol. 2023. PMID: 37969646 Free PMC article.
-
Development, validation, and clinical utility of risk prediction models for cancer-associated venous thromboembolism: A retrospective and prospective cohort study.Asia Pac J Oncol Nurs. 2025 Mar 22;12:100691. doi: 10.1016/j.apjon.2025.100691. eCollection 2025 Dec. Asia Pac J Oncol Nurs. 2025. PMID: 40291141 Free PMC article.
-
Development of a nomogram model to predict 30-day mortality in ICU cancer patients with acute pulmonary embolism.Sci Rep. 2025 Mar 18;15(1):9232. doi: 10.1038/s41598-025-93907-4. Sci Rep. 2025. PMID: 40097605 Free PMC article.
-
Anticoagulation in special patient populations with atrial fibrillation.Herz. 2021 Aug;46(4):323-328. doi: 10.1007/s00059-021-05042-1. Epub 2021 Jul 5. Herz. 2021. PMID: 34223913 Review. English.
-
The Role of Anticoagulation on Venous Thromboembolism Primary Prophylaxis in Low- to Intermediate-Risk Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Asian Pac J Cancer Prev. 2024 Jul 1;25(7):2237-2246. doi: 10.31557/APJCP.2024.25.7.2237. Asian Pac J Cancer Prev. 2024. PMID: 39068554 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials